MDXG
NASDAQ · Biotechnology
Mimedx Group Inc
$3.88
-0.09 (-2.27%)
Financial Highlights (FY 2026)
Revenue
348.07M
Net Income
40.38M
Gross Margin
82.6%
Profit Margin
11.6%
Rev Growth
+16.1%
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 348.07M | 299.90M | 190.63M | 232.96M |
| Gross Profit | 287.37M | 247.60M | 62.11M | 75.91M |
| Operating Income | 53.12M | 41.19M | 26.66M | 33.71M |
| Net Income | 40.38M | 31.32M | 27.70M | 27.53M |
| Gross Margin | 82.6% | 82.6% | 32.6% | 32.6% |
| Operating Margin | 15.3% | 13.7% | 14.0% | 14.5% |
| Profit Margin | 11.6% | 11.0% | 14.5% | 11.8% |
| Rev Growth | +16.1% | +16.1% | +8.9% | +19.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 15.80M | 15.80M | 233.39M | 246.36M |
| Total Equity | 225.71M | 225.71M | 355.89M | 342.73M |
| D/E Ratio | 0.07 | 0.07 | 0.66 | 0.72 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 54.29M | 44.44M | 34.17M | 44.70M |
| Free Cash Flow | — | — | 29.04M | 38.48M |